Literature DB >> 1973217

Developments in pertussis immunisation in Japan.

M Kimura1, H Kuno-Sakai.   

Abstract

In Japan acellular pertussis vaccine has totally replaced whole-cell vaccine since 1981. The vaccine is given in combination with diphtheria and tetanus toxoids to children aged 24-48 months; three doses are given with intervals of 3-8 weeks and the fourth dose (booster) is given 12-18 months after the third. There has been a steady decline in cases of pertussis and deaths from the disease since 1979. Comparison of the rates of adverse reactions to whole-cell vaccine in 1973-74 and to acellular vaccine in 1979-80 showed lower rates of fever and of local reactions with the acellular vaccine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973217     DOI: 10.1016/0140-6736(90)91530-n

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  Pertussis vaccine controversies and acellular pertussis vaccine.

Authors:  Raju C Shah; Anuj R Shah
Journal:  Indian J Pediatr       Date:  2003-06       Impact factor: 1.967

2.  Is Bordetella pertussis clonal?

Authors:  M N Khattak; R C Matthews; J P Burnie
Journal:  BMJ       Date:  1992-03-28

Review 3.  The complicated task of monitoring vaccine safety.

Authors:  S S Ellenberg; R T Chen
Journal:  Public Health Rep       Date:  1997 Jan-Feb       Impact factor: 2.792

Review 4.  An overview of the status of acellular pertussis vaccines in practice.

Authors:  A L Lopez; D A Blumberg
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

Review 5.  Acellular pertussis vaccines.

Authors:  E Miller
Journal:  Arch Dis Child       Date:  1995-11       Impact factor: 3.791

Review 6.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

7.  Investigation in a murine model of possible mechanisms of enhanced local reactions to post-primary diphtheria-tetanus toxoid boosters in recipients of acellular pertussis-diphtheria-tetanus vaccine.

Authors:  Masaki Ochiai; Yoshinobu Horiuchi; Chun-Ting Yuen; Catpagavalli Asokanathan; Akihiko Yamamoto; Kenji Okada; Michiyo Kataoka; Kevin Markey; Michael Corbel; Dorothy Xing
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

9.  Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.

Authors:  G Kanra; M Ceyhan; D Vandevoorde; H Bogaerts
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

Review 10.  Quest for life-long protection by vaccination.

Authors:  W R Dowdle; W A Orenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.